LNP-based mRNA delivery across BBB for neurological disorders

View profile for Lorenz Mayr

Managing Director - BioMedTech Consulting GmbH

Systemic LNP-based delivery of mRNA into the brain (through BBB): Recent advances in lipid nanoparticle (LNP) technology enable systemic delivery of mRNA across the blood-brain barrier, offering promising therapeutic potential for glioblastoma and other central nervous system disorders.  As shown in the attached publication in Science Advances (and similar ones below), incorporation of the serotonin (5-HT3) receptor ligand SR-57227 into ionizable lipids has been used to effectively facilitate brain-targeted mRNA delivery, which can be used to encode proteins like IL-12 for transient expression and/or genome/epigenome editors for long-lasting changes, highlighting significant implications for neurological disease treatment in the future. Original publication: https://lnkd.in/e6dBRTV3 Further reading: https://lnkd.in/eVCJfxmS https://lnkd.in/ekEkaD3E https://lnkd.in/ep-bYdeD https://lnkd.in/eNV2MNDv https://lnkd.in/eRCEA2JN

  • diagram, text
Peter Nell

𝘊𝘰-𝘧𝘰𝘶𝘯𝘥𝘦𝘳, 𝘊𝘌𝘖 𝘚𝘵𝘦𝘢𝘭𝘵𝘩 𝘉𝘪𝘰𝘵𝘦𝘤𝘩

1w

Great progress, we might still need better specificity regarding various cell types in the brain, but looks like a nice distribution initially. On a different note, I see more and more papers with only Chinese names on it but the location is in the US. Wonder what is going on with the US education? Where is the push for diversity?

Like
Reply
Prof. Georgi Momekov, DSc

Dean of the Faculty of Pharmacy at Medical University of Sofia, MUS

1w

An elaborate Trojan horse strategy for these unwieldy molecular Achaeans

Like
Reply
Sundaresan Rajesh

Scientific Leader at GSK

4d

Thanks for sharing, Lorenz. Unloading complete mRNA cargo will probably be the next big reveal..

Like
Reply
Jay Chaplin

Director, Head of Immunology | Drug Discovery & Design Consultant | Immunology | CGT | Cross-Functional Collaboration | Conflict Resolution | Research and Development | Product & Business Development | Kayaker

1w

This is a fantastic advance, and smart. I remain a bit concerned though as the ionizable lipid component is necessary for mRNA loading & release and also produces significant inflammation - something you really don't want in the brain. Targeting is half of the battle, now we need ionizable lipid components that still work well for delivery but have a reduced inflammatory profile.

Adhurim Bresa

PhD Candidate in Pharmaceutical Sciences, University of Medicine, Tirane | Teaching Assistant at University of Prishtina, Kosove

6d

💡 Great insight

Like
Reply
Matthias Bozza

Company Builder | Drug Developer | Gene and Cell Therapy | Oncology

1w

The progress is impressive considering where we started not so long ago.

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories